Results 71 to 80 of about 8,768 (188)

Role of Bosentan in Pulmonary arterial hypertension

, 2007
Pulmonary arterial hypertension is an invariably fatal clinical condition often complicating some medical conditions like the HIV and sickle cell disease amongst others.
J A Saleh, Saleh, J A
core   +1 more source

Successful Treatment with Bosentan of Lower Extremity Ulcers in a Scleroderma Patient

Case Reports in Medicine, 2013
Digital ulcers are a well-known problem in patients with systemic sclerosis. Lower extremity ulcers are less prevalent but are also a challenging and underestimated complication of the disease causing important pain and morbidity.
Alix Naert, Petra De Haes
doaj   +1 more source

Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan

, 2012
Background This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients.
Bleda Silvia, Acin Francisco, Varela Cesar, De Haro Joaquin, Esparza Leticia   +4 more
core   +1 more source

Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes [PDF]

, 2018
Experimental evidence suggests that endothelin 1 (ET-1) is involved in the development of retinal microvascular abnormalities induced by diabetes. The effects of ET-1 are mediated by endothelin A- and B-receptors (ETA and ETB).
Olga Simó-Servat, Luís Arias, Joel Sampedro, Ticó, Josep Ramon, Solà-Adell, Cristina, Marta Garcia-Ramírez, Durán, Vicente, Arias Barquet, Lluís, Simó-Servat, Olga, Cristina Hernández, Cristina Solà-Adell, Vicente Durán, Garcia-Ramírez, Marta, Montoro, Bruno, Rafael Simó, Patricia Bogdanov, Josep Maria Suñé-Negre, Sampedro, Joel, Hernández, Cristina, Guerrero, Marta, Ramos, Hugo, Hugo Ramos, Bogdanov, Patricia, Simó Canonge, Rafael, Josep Ramon Ticó, Suñé-Negre, Josep Maria, Marta Guerrero, Bruno Montoro   +27 more
core   +1 more source

The Effect of Particle Size and Surface Roughness of Spray-Dried Bosentan Microparticles on Aerodynamic Performance for Dry Powder Inhalation

Pharmaceutics, 2020
The purpose of this study was to prepare spray dried bosentan microparticles for dry powder inhaler and to characterize its physicochemical and aerodynamic properties.
Yong-Bin Kwon, Ji-Hyun Kang, Chang-Soo Han, Dong-Wook Kim, Chun-Woong Park   +4 more
doaj   +1 more source

Towards a Safe Pathway to Biological Parenthood for Pulmonary Arterial Hypertension

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) carries a high risk of maternal morbidity and mortality in pregnancy, and current guidelines advise against conception. For women with PAH who wish to have genetically related children, in vitro fertilisation (IVF) combined with gestational surrogacy presents a viable and increasingly safe alternative ...
Jamie D. Ingram, Scott M. Nelson, Melanie J. Brewis, Martin K. Johnson, Colin Church   +4 more
wiley   +1 more source

Bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial

, 2008
Objectives Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Background CTEPH
M. Delcroix, L. Perchenet, G. Simonneau, X. Jais, D'ARMINI, ANDREA MARIA, A. Morganti, E. Mayer, M. M. Hoeper, A. Torbicki, H. A. Ghofrani, G. Somonneau, L. J. Rubin, J. Pepke Zaba, I. M. Lang, P. Jansa   +14 more
core   +1 more source

Patient Perspectives on Palliative Care in Pulmonary Arterial Hypertension in the United States

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
ABSTRACT Palliative care can be offered concurrently as a treatment option to patients with pulmonary arterial hypertension (PAH) to relieve symptoms and improve quality of life. However, it is infrequently used and is associated with misconceptions. Limited studies have reported patients' perspectives of palliative care as a treatment option for PAH ...
Karim El‐Kersh, Rebecca Crawford, Hilary DuBrock, Peter Classi, Phuong Phan, Lori McLeod, Benjamin Wu, Denise Sese   +7 more
wiley   +1 more source

BOSENTAN, A NON-SPECIFIC ENDOTHELIN ANTAGONIST, STIMULATES FRACTURE HEALING

, 2007
It is assumed that bosentan, a non-selective ET-1 receptor antagonist, will enhance fracture healing. The aim of this prospective randomized controlled study was to investigate the effects of transcutaneous bosentan administration into diaphyseal bone ...
Bicimoglu, Ali, KORKUSUZ, PETEK, Muratli, Hasan H., Ercan, Z. Sevim, Korkusuz, Feza   +4 more
core   +2 more sources

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient

, 2009
Christopher J Valerio, John G CoghlanDepartment of Cardiology, Royal Free Hospital, London, UKAbstract: Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcomes. Bosentan is an oral endothelin-1 receptor antagonist (ERA)
Christopher J Valerio, John G Coghlan
core